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Abstract Glycosylation is a major pathway for posttransla- 
tional modification of tissue protein and begins with non- 
enzymatic addition of carbohydrate to the primary amino 
groups. Excessive glycation of tissue protein has been implicated 
in the pathogenesis of diabetes and ageing. While glycation of 
aminophospholipids has also been postulated, glycated amino- 
phospholipids have not been isolated. Using normal phase HPLC 
with on-line electrospray mass spectrometry we found glycated 
ethanolamine phospholipids to make up 10-16% of the total 
phosphatidylethanolamine (PE) of the red blood cells and plasma 
of the diabetic subjects. The corresponding values for glycated 
PE of control subjects were 1-2%. 
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bovine brain phosphatidylinositol (PI) and sphingomyelin (SPH) were 
obtained from Sigma Chemical Co., St. Louis, MO. All chemicals 
were of reagent grade quality, while the solvents were of chromato- 
graphic purity and were obtained from local suppliers. The purity of 
the reference compounds was ascertained by thin-layer chromatogra- 
phy (TLC) [3,7]. 
2.1. Isolation of phospholipids from blood 
Blood was obtained from six diabetic patients and six non-diabetic 
donors. The diabetics were selected for elevated blood glucose levels 
indicated by their content of glycosylated hemoglobin (9-15%). 
EDTA blood was centrifuged (2300xg for 10 min) in a swinging 
bucket rotor to separate the plasma from the red cells. The cells 
were washed three times with five volumes of phosphate buffered 
saline (150 mM NaC1, 50 mM sodium phosphate, pH 8.0) and cen- 
trifuged (2300xg for 10 min). The red blood cell phospholipids were 
extracted according to Rose and Oaklander [8]. The plasma phospho- 
lipids were extracted with chloroform-methanol 2:1 modified from 
Folch et al. [9]. Glucosylated PE could be stored at -20°C in neutral 
chloroform methanol for several days without decomposition. The 
Schiff base dissociated in dilute acetic acid. 
1. Introduction 
We have previously reported on the identification of high 
molecular weight secondary products of peroxidation of stan- 
dard lipids and lipoproteins during in vitro incubation with 
tert-butyl hydroperoxide [1,2] or copper ions [3,4]. Using these 
products as reference standards we have identified lipid ester 
hydroperoxides and core aldehydes in plasma and atheromas 
of patients with atherosclerosis and diabetes [5]. Bucala et al. 
[6] have postulated that aminophospholipids might react with 
the increased glucose in diabetes to form Schiff bases, which 
promote fatty acid oxidation. The glycation products of ami- 
no group-containing phospholipids, however, have never been 
isolated and their role in lipid peroxidation has not been di- 
rectly determined. We have recently synthesized glucosylated 
phosphatidyl-ethanolamine (PE) and phosphatidylserine (PS) 
and have determined their chromatographic properties [7]. In 
the present study we have used the glucosylated aminopho- 
spholipids as reference compounds to identify and quantitate 
glucosylated PE in lipid extracts from red blood cells and 
plasma of diabetics and of control subjects. 
2. Materials and methods 
Glucosylation products of the dipalmitoyl species of PE and PS as 
well as the PE of egg yolk and PS of human red blood cells were 
available from previous work [7]. Non-glucosylated gg yolk PE and 
bovine brain PS, as well as egg yolk phosphatidylcholine (PC) and 
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2.2. NaCNBH4 reduction 
Aliquots of phospholipids containing lucosylated PE in chloro- 
form were reduced by adding freshly prepared NaCNBH4 in metha- 
nol (final concentration 70 mM) as previously described [7]. 
2.3. Normal phase HPLC LC/ESIIMS of phospholipids 
Normal phase HPLC separations of phospholipids were performed 
on Spherisorb 3 micron columns (100 mmx4.6 mm ID, Analtech, 
Deerfield, IL) installed into a Hewlett-Packard (Palo Alto, CA) Model 
1090 Liquid Chromatograph connected to a Hewlett-Packard Model 
5988B Quadrupole mass spectrometer quipped with a nebulizer as- 
sisted electrospray interface. The column was eluted with a linear 
gradient of 100% Solvent A (chloroform/methanol/30% ammonium 
hydroxide, 80:19.5:0.5, by vol) to 100% Solvent B (chloroform/ 
methanol/water/30% ammonium hydroxide, 60:34:5:0.5, by vol) in 
14 min, then at 100% B for 10 min [10]. Both negative and positive 
ionization spectra were taken in the mass range 40~1100. Selected 
ion spectra were retrieved from the total ion spectra by computer. The 
molecular species of the various glycerophospholipids were identified 
on the basis of the molecular mass provided by the mass spectrometer, 
the knowledge of the fatty acid composition of the aminophospholipid 
class, and the relative lution order (the less polar long chain species 
emerging ahead of the more polar short chain species) of the phos- 
pholipids from the normal phase column. 
3. Results 
Fig. 1A shows the total positive ion current profile of 
red blood cell phospholipids as obtained by LC/MS for a 
50 year old patient with diabetes. Only PC, SPH and lyso- 
phosphatidylcholine (LPC) are seen as they are readily io- 
nized under these conditions, but PE can also be discerned. 
The PC and SPH are resolved into two or more subfractions 
with the longer chain species being eluted earlier than the 
shorter chain species. LC/ESI/MS yielded molecular masses 
S0014-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
SSDI S00 l 4 -5793(96)00064-6  
78 A. Ravandi et aL/FEBS Letters 381 (1996) 77~81 
DIABETIC RBC: ibundance A TIC (POS] / 
aoooo I /~ PC TOTAL PHOSPHOLIPIDS /I ~I LPC 
~oooo q SPH /~ 
20000 ~ ~ . ~ ' ~  , \  P_E i " 
0 I . . . . . .  ~ . . . . .  ~ i . . . .  i . . . .  , . . . .  , . . . .  i . . . .  - i  . . . .  , 
"£me--> 2JO0 4.00  6.'00 8.00 i0.00 12.00 14.00 16.00 18.00 
~LLndance Average of 10.418 to 10.479 min. 880 
6000 
C [M+I]" 
sooo 878 
4oo0 820 906 
aooo 794 I 852 876 9041 
2ooo 826 I L 902 908 
,ooo i ,II II 8,,1  
0 . . . .  I , t . r ~ I . . . .  . . . . .  I . . . . . . .  I .  J I , , . . . . . .  I,.,J , J  ~ ,l, ,,I i~L ,  I , ,  i d l  . . . . . .  , . . . .  ' " "  I 
el--> 600 650 700 750 800 850 900 950 
Fig. 1. LC/ES/MS of the phospholipids of red blood cells of a male diabetic subject with 9% glycation of hemoglobin. (A) Total positive ion 
profile; (C) mass spectra veraged over the front part of the earliest emerging PC peak (10.418-10.479 min). PE, phosphatidylethanolamine; 
PC, phosphatidylcholine; SPH, sphingomyelin; LPC, lysophosphatidylcholine. The masses in C correspond to the [M+I] + ions of the 18:0- 
18:1 (m/z 908), 18:1-18:1 (m/z 906); 18:1-18:2 (m/z 904); 16:0-20:4 (m/z 902); 16:0 18:0 (m/z 882); 16:~18:1 (rrdz 880); 16:0-18:2 (rn/ 
z 878); and 16:0~16:0 (m/z 854) of glucosylated PE. HPLC conditions: Column, Spherisorb 3 micron (100 mm×4.6 mm ID, Analtech, Deer- 
field, IL); Solvent: Linear gradient of 100% Solvent A to 100% Solvent B in 14 min, then Solvent B for 10 rain. Solvent A: chloroform/metha- 
nol/30% ammonium hydroxide (80: 19.5:0.5, by vol). Solvent B: chloroform/methanol/water/30% ammonium hydroxide (60:34:5.5:0.5, by 
vol). MS instrumentation and operating conditions were as given in section 2. 
characteristic of the major molecular species in each phos- 
pholipid class, except for the species associated with the 
front of the first PC peak, which were of higher molecular 
mass. 
Fig. 1C gives the mass spectra averaged over the front part 
of the earliest emerging PC peak (10.418-10.479 rain) in Fig. 
1A. The major masses correspond to the [M+I] + ions of the 
mono- and di-unsaturated species of glucosylated PE, e.g. m/z 
852 (16:0-16 : 1), m/z 878 (16:0-18:2),  m/z 880 (16:0-18 : 1), 
m/z 882 (18:0-16:0),  rn/z 902 (18 :~18:2) ,  m/z 904 (18:1 
18:2), m/z 906 (18:1-18:1) and m/z 908 (18:0-18:1). We 
have shown previously [7] that glucosylated PE emerge with 
the front of the first PC peak, while glucosylated PS overlap 
with the LPC peak. The masses at m/z 794 and 820 were 
assigned to the 18:0"-20:4 and 18:0"-22:5 and other isoba- 
ric alkenylacyl PC species, respectively, to which they also 
correspond in HPLC retention time. 
Fig. 2 gives single ion plots for the major species of glycated 
PE in Fig. 1C along with the proposed identities. These ions 
appeared just ahead of those corresponding to the major poly- 
unsaturated species of PC, but there were some overlaps. The 
opportunity for overlapping of co-incidence ions from PC and 
glucosylated PE was eliminated by sodium cyanoborohydride 
reduction of the glucosylated PE. The reduction increased the 
mass of the [M+I] + ions by two mass units and led to a 
marked increase (14 min) in HPLC retention time, which re- 
suited in the elution of the glucosylated PE species in the 
sphingomyelin range [7]. Similar results were obtained with 
the red blood cells of the other diabetic subjects. 
Fig. 3A shows the total positive ion current profile of the 
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Fig. 2. Single ion plots of the masses corresponding to the [M+I] + ions of the major molecular species of glycated PE from red blood cells of 
a diabetic subject. The ions are identified as shown in the figure. LC/ESI/MS conditions are as given in Fig. 1. 
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Fig. 3. LC/ESIMS of  plasma phospholipids of a Female diabetic with 12% glycation of hemoglobin. (A) Total positive ion current profile; 
(C) mass spectra averaged over the front part of the earliest emerging PC peak (10.2126-10.471 min). Phospholipid classes are identified as in 
Fig. 1. The masses in (C) correspond to the glucosylated PE as indicated in Fig. 4. LC/ESI/MS conditions were as given in Fig. 1C. 
plasma phospholipids as obtained by normal phase LC/ESI/ 
MS for another patient with diabetes. The phospholipid 
classes yield a pattern slightly different from that seen for 
the red cells. However, PC is again split into two peaks, 
with the earlier emerging one overlapping with glucosylated 
PE. There is relatively more SPH, again being split into sub- 
fractions, and LPC in the plasma than in the red cells. Again 
the various phospholipid classes gave molecular masses char- 
acteristic of the major molecular species, except for the front 
of the first PC peak, which contained a series of higher mo- 
lecular weight components corresponding to glucosylated PE. 
Fig. 3C shows that the higher masses are concentrated at 
the front of the earliest emerging PC peak (10.226-10.471 
min) in Fig. 3A. The major masses in the averaged spectrum 
correspond to the [M+I] + ions of glucosylated mono- and di- 
unsaturated species of PE as noted above for the red cells, e.g. 
m/z 852, ndz 876, m/z 878, mlz 880, m/z 904, and m/z 908). 
The ions at rrdz 794 and 822 correspond to the 18:0"-20:4 
and 18 : 0"-22 : 4 and isobaric alkenylacyl species of PC, which 
are eluted earlier than the other PC species because of the 
lower polarity. The proportions of the glucosylated PE species 
differ only slightly from those of the red cells. 
Fig. 4 gives single ion plots for the glucosylated PE masses 
in Fig. 3C along with the proposed identities of the species. 
Again the glucosylated species exhibited the increases in the 
mass and in retention time as a result of the cyanoborohy- 
dride reduction, as already noted for the glucosylated PE of 
the red cells. Neither positive nor negative ion mode indicated 
the presence of any glucosylated PS in the red cells or in 
plasma, although PS was demonstrated to be readily glucosy- 
lated in vitro [7]. 
Table 1 compares the species of the diacyl, alkenylacyl, and 
glycated iacyl PE from the red cells of diabetic and control 
subjects. Only the diacyl species have become glycated and 
not the alkylacyl or alkenylacyl ones, although the plasmalo- 
genic species make up 50% of total red blood cell PE. Further- 
more, the glycation of the diacyl PE appears not to be ran- 
dom, which contrasts with random glycation of both diacyl 
and plasmalogenic species in vitro [7]. It may be noted that 
several of the glucosylated species represent very minor red 
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Fig. 4. Single ion plots of the masses corresponding to [M+I] + of the molecular species of glucosylated PE as obtained in Fig. 3C for the plas- 
ma of a female diabetic subject. The ions are identified as shown in the Fig. 4. LC/ESI/MS conditions are as given in Fig. I. 
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Table 1 
Glycated 
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diacyl (GLY-PE), diacyl (PE) and alkenylacyl (PE") PE in red blood cells of control and diabetic subjects (mole %)~ 
Molecular species Controls 
GLY-PE 
Diabetics 
PE PE" GLY-PE PE PE" 
16:0 16:0 7.1_+1.1 1.2_+0.2 6.8_+0.8 2.7_+0.5 
16:0 18:0 1.0±0.3 0.3_+0.1 2.5±0.6 1.0_+0.2 
16:0 18 : 1 26.9 ± 5.3 5.3 _+ 1.6 20.2 _+ 3.7 23.6 _+ 4.2 2.9 _+ 0.8 
16:0-18:2 70.3_+6.9 11.8±3.2 21.7±4.1 8.5_+2.6 0.5_+0.1 
16:1 18:3 1.6_+0.5 0 .1±0.1 14.2±2.3 0.8±0.2 
18:0-18:0 0.1±0.1 0.9±0.2 0.3±0.1 
18:0-18:1 5.1_+1.4 3.7_+1.1 1.9_+0.8 5.0_+1.8 1.7_+0.7 
18:0-18:2 11.2±2.5 8.2_+1.8 3.4_+0.9 2.7±0.8 7.0_+1.9 2.1±0.9 
18:1 18:2 8.3_+2.3 0.9±0.2 20.6_+4.3 9.4_+2.1 0.5_+0.1 
16:0-20:4 11.7±2.6 6.1_+1.0 3.1±0.6 9.8±1.8 4.6_+1.2 
16:0-20:5 6.7±1.5 0.7_+0.1 3.5±0.7 2.1_+0.7 1.3±0.2 
16:1 20:5 2.6±0.4 1.5±0.3 3.0_+0.5 
18:0-20:3 2.5±0.6 0.5_+0.1 
18:0-20:4 8.1 ± 1.8 23.5 _+4.2 7.1 ± 1.6 18.8 ± 3.6 
18:1 20:4 8.8 ±2.1 11.0_+2.6 7.0_+ 1.8 8.7± 1.1 
16.0-22.6 3.4±0.8 1.1_+0.3 4.0±1.2 6.4±1.6 
18.1 22.6 5.9 0.6 3.5 
18.0-22.3 0.1±0.1 1.1_+0.2 0.1_+0.1 0.3_+0.1 
18.0-22.4 0.1±0.1 0.7_+0.1 1.3±0.4 
18.0-22.5 0.6±0.1 11.5_+2.1 0.7_+0.2 10.2_+2.0 
18.0 22.6 1.0_+0.3 11.3±2.3 2.4_+0.9 19.3±3.7 
18.1-22.6 1.1±0.2 5.1_+1.8 3.9±0.8 9.0_+1.4 
Other 3.0_+0.8 1.9_+0.4 4. l±1.7 1.5±0.5 3.3_+0.8 5.1±1.7 
Total 1.1±0.2 54.0_+3.5 44.9±4.1 9.8_+1.1 40.1_+2.2 50.1_+2.9 
~As estimated from uncorrected ion intensity by LC/ESI/MS. Means_+ S.D. (n = 6). 
cell PE components of control and diabetic subjects. The pro- 
portions of the major molecular species within the underiva- 
tized PE were comparable in the controls and diabetics, in- 
cluding a high proportion of the plasmalogens [11,12]. 
Table 2 shows that the glucosylated PE made up a some- 
what higher proportion of plasma than red cell PE, although 
there was much less total PE in plasma. On the basis of the 
major PE species it was calculated that 16% and 10% of the 
diacyl PE of plasma and red cells, respectively, became glu- 
cosylated. The overall glycation of PE (10-16°/,,) was similar 
to the overall glycation of hemoglobin (9 15%) in the diabetic 
patients. The control red cells and plasma showed less than 
1% glucosylation. 
4. Discussion 
Although glucose is the least reactive of the monosacchar- 
ides in Schiff base formation [14], it has been suggested [6] 
that it might react with aminophospholipids and play a role in 
production of lipid advanced glycation end-products (AGE). 
In support of this hypothesis Bucala et al. [6] have reported 
evidence for the formation of phospholipid-linked AGE in 
vitro, mimicking the absorption, fluorescence and immuno- 
chemical properties of AGE that result from advanced glyco- 
sylation of proteins. Furthermore, AGE-EL ISA analysis of 
LDL specimens isolated from diabetic individuals revealed 
[6] increased levels of both apoprotein and lipid-linked 
AGE, when compared to specimens obtained from normal, 
non-diabetic controls. Glycated aminophospholipids were 
not isolated from any of the sources. 
The effect of diabetes on blood lipid composition is con- 
troversial [15]. Some studies had shown decreased [16] and 
others increased [17] PE levels in the red blood cells of dia- 
betics. In one instance [17] an unidentified phospholipid had 
been detected by thin-layer chromatography (TLC). We esti- 
mated the Rf  value of this unknown as 0.35 corresponding to 
an Rf  value of 0.37 obtained for the standard glycated PE in 
the same solvent system in our laboratory. Still other studies 
[18] have shown significantly increased membrane lipid perox- 
idation and a formation of an adduct of phospholipids and 
malonyldialdehyde in erythrocytes from diabetic compared to 
erythrocytes from non-diabetic subjects. The degree of mem- 
Table 2 
Content of glucosylated PE in plasma and red blood cells of diabetics and control subjects as estimated on basis of total, diacyl and the palmi- 
toyl-linoleoyl species of PE ~ 
Subjects % Total PE % Diacyl PE % 16:0-18:2 PE 
Diabetics 
RBC 10.2+2 18.4_+3 17.6_+2 
Plasma 16.1 _+ 3 27.7 _+ 3 
Non-diabetics 
RBC 1.2_+0.5 5.6_+2 6.1 _+4 
Plasma 2.3 _+ 1 1.5 _+ 0.5 
~The percentages were calculated by expressing the sum of intensities in the various glucosylated species as a percentage of the total of each species 
or group or species. Means _+ S.D. (n = 4). 
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brane lipid peroxidation was significantly correlated with the 
level of glycosylated hemoglobin. 
Because of the apparent preferential glucosylation of the 
diacyl PE species, it would have been anticipated that the 
residual PE in the red blood cells of diabetics would be in- 
creased in plasmalogens. This was not obvious in the present 
experiments. Previously Freyburger et al. [17] had noted mini- 
mal amounts of dimethylacetals among the methylation pro- 
ducts of the red blood cell PE. However, these workers also 
failed to detect he normal amounts of dimethylacetals in the 
PE of control subjects [17]. 
In view of random glycation of diacyl and alkenylacyl PE in 
vitro [7], the preferential glycation of the diacyl species of PE 
of the red blood cells and plasma observed in vivo in the 
present study requires an explanation. The phospholipid 
classes of the lipid bilayer of the red blood cell are known 
to be extensively segregated [19,20], and work with liposomes 
has demonstrated [21] that the sidedness of the free amino 
group influences the peroxidation of the aminophospholipids 
and their interaction with the secondary peroxidation pro- 
ducts. Alternately, the diacyl and alkenylacyl species of PE 
might be subject o differential interaction with proteins, pro- 
tecting the alkenylacyl and exposing the diacyl species of PE 
to glucosylation, regardless of their location in the bilayer. It 
is also possible that glucosylated alkenylacyl species of PE 
might have become preferentially deglucosylated by some of 
the defence mechanisms operating in the red blood cell mem- 
brane or plasma. 
The failure to isolate glycated PE from the red blood cells 
of diabetics previously may have been due to the relatively 
easy dissociation of the Schiff base in the presence of dilute 
acid frequently employed in phospholipid recovery from TLC 
(e.g. organic solvents with 10% acetic acid). Using reference 
standards we had noted [7] that alkaline solvent systems were 
better suited than acid solvent systems for recovery of gly- 
cated PE from in vitro and in vivo samples. The mild electro- 
spray ionization facilitated the detection of glycated amino- 
phospholipids, which was not possible with fast atom 
bombardment mass spectrometry [7]. 
The glucosylation of a major proportion of the PE would 
be anticipated to affect the structure and function of the red 
cell membrane due to alterations in charge and the bulk of the 
glucosylated polar head group. It would also be expected to 
affect the susceptibility of the glucosylated phospholipid to 
phospholipases. We have reported elsewhere [13] that gluco- 
sylated PE is more susceptible to peroxidation than non-glu- 
cosylated PE, which is more resistant to peroxidation than PC 
[21]. Recently, Zommara et al. [22] have reported the inhibi- 
tory effect of ethanolamine plasmalogen on lipid peroxidation 
to be due to binding of iron and copper to liposomal lipids. It 
is therefore possible that hyperglycemia might play a role in 
promoting membrane lipid disorganization leading to perox- 
idation and atherosclerosis in diabetics. 
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